CELC ▲ +0.4% - Celcuity Inc.
$CELC - Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
23-OCT-2026 09:15 AM ET
Share this post
More filings for $CELC
CELC ▼ -0.1% - Celcuity Inc.Oct 5, 2026CELC ▲ +0.9% - Celcuity Inc.Oct 2, 2026CELC ▲ +4.0% - Celcuity Inc.Sep 30, 2026CELC ▲ +1.1% - Celcuity Inc.Sep 17, 2026CELC ▼ -0.2% - Celcuity Inc.Sep 1, 2026CELC - Celcuity Inc. - SEC Filing Update (11-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 11, 2026
View full $CELC filing history →💬 Comments
Loading comments…
Leave a comment